Patient adherence programs are often the highest-ROI patient marketing investment a chronic-disease brand can make because they protect prescriptions you have already won, improve the experience after the script is written, and create an outcomes story that matters to both brands and payers. Most pharma teams still underinvest here. They fund awareness, launch media, and HCP promotion, then leave the refill journey to a thin layer of reminders and fragmented support.
That gap is expensive. Medication nonadherence drives roughly \$100 billion to \$300 billion in annual U.S. healthcare costs, about one in five new prescriptions is never filled, and among prescriptions that are filled, roughly 50% are taken incorrectly (CDC Grand Rounds; PubMed). The World Health Organization also reports that adherence to long-term therapy for chronic illness in developed countries averages 50% (WHO adherence report).
For a brand team, that means adherence is not a soft patient-support issue. It is a revenue protection engine, a retention problem, a patient-experience problem, and increasingly a payer-value problem all at once. If you market in chronic disease, improving adherence is where patient empathy and commercial logic finally point in the same direction.
Table of Contents
- The adherence crisis
- The 5 dimensions of adherence
- What modern patient adherence programs actually do
- The 6 components of a high-performing adherence program
- How to measure adherence
- Compliance considerations
- AI in medication adherence marketing
- The brand-payer ROI story
- Common mistakes
- FAQ
- Build a smarter adherence engine with XDS Health
The adherence crisis
The adherence crisis starts after intent is already there. A clinician prescribes. A patient leaves the office with some degree of hope. Then real life shows up: cost, side effects, confusion, forgetfulness, transportation gaps, prior auth delays, low health literacy, competing family demands, and the simple emotional drag of living with a chronic condition.
The data is blunt. About 20% of new prescriptions are never filled, and about half of filled prescriptions are taken incorrectly with respect to timing, dosage, frequency, or duration (CDC Grand Rounds; PubMed). The economic burden is equally blunt: direct U.S. healthcare costs tied to nonadherence have been estimated at approximately \$100 billion to \$300 billion annually (CDC Grand Rounds; PubMed).
For chronic-disease brands, the business impact compounds over time. Every missed refill weakens persistence, increases avoidable drop-off, and reduces the lifetime value of the patient relationship. On large brands, even a one-point lift in refill behavior can translate into materially more retained scripts. The exact dollar figure varies by population size, gross-to-net realities, and duration of therapy, but the strategic principle is simple: you usually do not need a massive adherence improvement to create meaningful revenue protection.
The human case is even stronger. The World Health Organization defined adherence as "the extent to which a person’s behaviour ... corresponds with agreed recommendations from a health care provider," and noted that long-term therapy adherence in developed countries averages 50% (WHO adherence report). WHO also made the point many marketers still miss: increasing the effectiveness of adherence interventions may have a greater population-health impact than improving specific medical treatments (WHO adherence report).
That is why patient adherence programs deserve boardroom attention. They sit at the intersection of access, education, behavior change, support design, and measurable outcomes. They are not a "nice to have" layer added after launch. They are part of the brand strategy.
The 5 dimensions of adherence
One reason medication adherence marketing often underperforms is that teams treat adherence like a memory problem. It is not. The WHO framework breaks adherence into five interacting dimensions: socioeconomic factors, health system and healthcare team factors, therapy-related factors, condition-related factors, and patient-related factors (WHO adherence report).
That framework matters because it forces better program design. If your program only sends reminders, it only addresses a small slice of the problem.
| Dimension | What it looks like in real life | What a brand should do |
|---|---|---|
| Socioeconomic | Cost burden, unstable routines, work constraints, transportation issues, limited caregiver support, and low health literacy can all interfere with consistent use (WHO adherence report). | Build affordability support, simpler channel options, multilingual content, and low-friction refill paths. |
| Healthcare team | Access to care, trust, follow-up quality, handoffs, and communication from the care team shape whether patients stay on therapy (WHO adherence report). | Connect digital reminders with nurse outreach, pharmacy coordination, and clear escalation rules. |
| Condition-related | Some conditions are asymptomatic, long-lasting, stigmatized, or emotionally draining, which makes adherence harder to sustain (WHO adherence report). | Tailor content to the reality of the disease, not just the mechanism of the drug. |
| Therapy-related | Side effects, dosing complexity, titration, device burden, or slow time-to-benefit can make patients stop early (WHO adherence report). | Prioritize expectation-setting, side-effect coaching, and onboarding support. |
| Patient-related | Beliefs, motivation, memory, confidence, anxiety, and personal routines influence whether the patient follows through (WHO adherence report). | Use behavioral design, trusted education, and personalized nudges instead of generic reminders. |
This is also where patient journey work becomes practical. If you need a framework for mapping the moments that drive drop-off, start with XDS’s guide to patient journey mapping for life sciences. Good journey maps do not just show touchpoints. They show where confidence falls apart.
What modern patient adherence programs actually do
Modern patient adherence programs do far more than send refill alerts. The strongest programs reduce barriers before they become abandonment, create support at predictable friction points, and adjust intervention intensity based on risk.
The CDC groups successful adherence strategies into four broad buckets: team-based care, patient education and empowerment, reducing barriers including cost, and health information technology tools that improve decision-making and communication (CDC Grand Rounds). That is a useful operating model for brands because it naturally pushes programs toward multichannel design.
| Intervention | What it solves | Common examples |
|---|---|---|
| Behavioral nudges | Forgetfulness, low motivation, weak routines | SMS reminders, app push alerts, calendar prompts, refill countdowns |
| Onboarding support | First-dose anxiety, confusion, side-effect fear | Welcome kits, starter education, nurse educator outreach, video walkthroughs |
| Affordability help | High out-of-pocket cost, delayed therapy start | Copay support, financial screening, benefit education, bridge support where appropriate |
| Education content | Low disease understanding, unrealistic expectations | Plain-language articles, short videos, FAQs, side-effect guidance, caregiver resources |
| Symptom and progress tracking | Low perceived benefit, therapy skepticism | Check-ins, symptom logs, device tutorials, progress dashboards |
| Human outreach | Complex cases, high-risk discontinuation | Nurse calls, pharmacist support, case management, escalation paths |
| Social reinforcement | Isolation, stigma, low confidence | Peer stories, moderated communities, caregiver involvement, rare-disease community content |
| Digital companions | Fragmented experience across channels | Companion apps, portals, integrated reminders, refill tools, educational workflows |
The best programs are orchestration systems. They combine SMS reminders, app or portal support, human outreach, and caregiver or community touchpoints into one journey. They do not assume one channel is enough. They also do not assume every patient needs the same level of intervention.
If you want to see how this broader support-design lens translates into digital execution, XDS’s patient support program design playbook is the right companion read. And if you work in low-incidence categories where trust and belonging matter even more, the rare-disease patient community strategy lens is especially useful.
The 6 components of a high-performing adherence program
1) Risk segmentation
High-performing adherence programs start by accepting that not all patients have the same risk of nonadherence. Some need simple refill prompts. Others need affordability support, side-effect management, or fast human intervention.
This is where segmentation should move beyond demographics. The most useful inputs are behavior and friction signals: prior adherence history, medication history, comorbidities, affordability barriers, complexity of regimen, digital engagement, refill timing, and patient-reported concerns. In a 2025 scoping review of 52 studies on machine learning approaches to predicting nonadherence, common predictors included prior adherence, medication history, comorbidities, and socioeconomic factors, while random forest and logistic regression appeared most often among top performers (PubMed scoping review).
For marketers, the implication is clear. Do not build one universal adherence journey. Build intervention tiers. Low-risk patients may only need lightweight reminders and education. Moderate-risk patients may need channel sequencing and affordability check-ins. High-risk patients may need nurse escalation, proactive outreach, and faster coordination with field reimbursement or patient support teams.
2) Onboarding and the early experience
The first 30 to 60 days often determine whether a patient becomes persistent or disappears. This is the window when questions are freshest, side effects feel most personal, and routines have not been formed yet.
A strong onboarding flow does three things. First, it reduces uncertainty: what happens next, when to take the therapy, what side effects to watch, when to call for help, and what "normal" looks like early on. Second, it reduces administrative friction: pharmacy coordination, benefits questions, prior authorization confusion, refill setup, and device training. Third, it reduces emotional friction: fear that the therapy is not working fast enough, worry about doing something wrong, or guilt about missing doses.
This is where patient-experience thinking matters more than campaign thinking. Your onboarding should sound like a trusted guide, not a promotional sequence. If your team tends to blur those lines, XDS’s breakdown of HCP vs. patient marketing strategy is a helpful reset.
3) Refill reminders
Refill reminders are table stakes, but they are still frequently underbuilt. Many brands rely on one message type, one cadence, and one call to action. That misses the point.
Good reminder systems are sequenced. They start before a patient runs out. They escalate if a refill does not happen. They change tone based on behavior. They route to the right next step, whether that is mail-order setup, pharmacy contact, affordability help, nurse support, or physician follow-up. They also respect patient preference. Some patients answer texts. Some need calls. Some want app notifications. Some rely on caregivers.
The CDC specifically highlights health information technology tools, coordinated care, and cost-reduction strategies as part of successful adherence improvement efforts (CDC Grand Rounds). In other words, reminders work best when they are connected to action, not when they are isolated notifications.
4) Copay and affordability support
Affordability is one of the fastest ways to lose persistence. Patients rarely say, "I am discontinuing because the economics no longer work." They just stop engaging.
A high-performing adherence program makes affordability support easy to find, easy to understand, and easy to act on. That can include eligibility education, copay support where permitted, financial-need routing, benefit explanations, and follow-up when cost becomes a barrier. Just as important, it means designing language that reduces shame. Patients do not want to feel screened out. They want to feel supported.
This is also where patient adherence programs become commercial in the best sense of the word. If cost is suppressing refills, solving cost is not peripheral to performance. It is the work.
5) Education and behavioral content
Education is not a library. It is a behavior tool.
The content that improves adherence is not generic disease-state filler. It is targeted content delivered at the right moment: first-dose guidance, managing expectations, side-effect coping, travel tips, device confidence, myths vs. facts, caregiver coaching, and reminders tied to patient goals rather than brand claims.
The CDC recommends educating and empowering patients to understand the treatment regimen and its benefits as a core adherence strategy (CDC Grand Rounds). That sounds simple, but in practice it means content teams need to write for anxiety, friction, and motivation, not just SEO. It also means structuring content so patients can find the answer they need in 30 seconds, not five minutes.
6) Crisis intervention and relapse prevention
Every adherence program needs a save strategy. Patients will hit rough patches: side effects, life disruptions, insurance changes, emotional burnout, perceived lack of efficacy, caregiver loss, or medication fatigue.
Brands that treat these moments as exceptions lose too many patients. Brands that treat them as predictable design points perform better.
A relapse-prevention layer should flag late refills, repeated content about side effects, low app engagement, support requests, and negative sentiment signals. It should define what happens next: message sequence, human outreach, pharmacy coordination, affordability review, or clinician communication. In a well-designed program, the patient never feels like they "failed." The program simply adapts.
How to measure adherence
If your medication adherence marketing program cannot prove impact, it will always be vulnerable to budget cuts. Measurement needs to be built into the program from the start.
Three metrics matter most:
| Metric | What it measures | Best use case | Important caveat |
|---|---|---|---|
| MPR | Medication Possession Ratio is calculated as days’ supply dispensed divided by days in the measurement window (JMCP/PMC). | Useful for simple refill-based monitoring and some historical comparisons. | Early fills can create overlap, so MPR can overestimate adherence and even exceed 100% (JMCP/PMC). |
| PDC | Proportion of Days Covered is the number of covered days divided by days in the measurement period (CMS Star Ratings Technical Notes; JMCP/PMC). | Best for plan-level and population-level measurement, especially when you want a conservative metric. | PDC caps each day at one covered day, so it does not exceed 100% (JMCP/PMC). |
| Persistence | Persistence is the length of time between initiation and the last dose before discontinuation (PubMed terminology paper; adherence taxonomy paper). | Best for understanding how long patients stay on therapy over time. | You still need reason codes to know why patients discontinued. |
CMS uses PDC for major Medicare medication adherence measures and applies an 80% threshold for adherence in those calculations (CMS Star Ratings Technical Notes). That is one reason PDC is often the most practical anchor metric for brand-payer conversations.
At the same time, persistence is critical if you market specialty therapies or any treatment where time on therapy is economically meaningful. PubMed’s terminology paper defines adherence or compliance as the extent to which a patient acts in accordance with the prescribed interval and dose, while persistence is the duration from initiation to discontinuation (PubMed terminology paper). The later taxonomy paper sharpens this further by defining adherence as a process made up of initiation, implementation, and discontinuation (adherence taxonomy paper).
In practice, the best measurement stack usually looks like this: - PDC for population reporting and payer alignment. - Persistence for understanding retained time on therapy. - Discontinuation reasons for operational improvement. - Program KPIs such as enrollment, open rates, response rates, nurse escalation completion, affordability resolution, and time-to-refill.
If you need a stronger framework for connecting adherence activity to business impact, XDS’s guide to healthcare marketing attribution and measurement is worth bringing into the planning process early.
Compliance considerations
Medication adherence marketing can be highly effective, but it only works long term if the compliance model is sound.
HIPAA and privacy
HHS states that refill reminders and other communications about a drug or biologic currently being prescribed are excluded from HIPAA’s definition of marketing, including adherence communications that encourage people to take prescribed medicines as directed, as long as any financial remuneration is reasonably related to the covered entity’s cost of making the communication (HHS refill reminder guidance). HHS also says this exception can cover prescriptions that lapsed within the last 90 calendar days, but not beyond that window (HHS FAQ; HHS refill reminder guidance).
That is useful, but it is not a blank check. Communications about switching to another drug, specific adjunctive therapies, or new formulations can fall outside the refill-reminder exception depending on how they are structured and funded (HHS refill reminder guidance). If a program uses business associates, HHS says payments to those partners must not exceed the fair market value of their services (HHS FAQ).
FDA promotional rules
Once an adherence experience becomes branded or starts making product claims, FDA promotional standards apply. FDA’s Office of Prescription Drug Promotion says prescription drug promotion must be truthful, balanced, accurately communicated, and not false or misleading (FDA OPDP). FDA guidance for consumer-directed broadcast advertisements also requires fair balance between effectiveness and risk information, a thorough major statement of the most important risks, and adequate provision for access to approved labeling (FDA broadcast ad guidance).
This is why adherence UX and regulatory review have to work together. If you need a digital design perspective on presenting safety information without wrecking usability, XDS’s piece on Important Safety Information best practices is highly relevant.
Anti-kickback and patient incentives
OIG has longstanding concerns about routine waivers of Federal healthcare program cost-sharing amounts, and says low risk generally depends on the waiver not being routine, not being advertised, and being based on a good-faith individualized assessment of financial need (HHS OIG FAQs). OIG also notes that remuneration likely to influence a beneficiary’s selection of a particular provider, practitioner, or supplier can raise risk under the Beneficiary Inducements CMP (HHS OIG FAQs).
For marketers, the practical lesson is simple: support programs must be designed with legal and compliance teams, not just approved at the end. Affordability help should solve access problems, not act like a disguised acquisition tactic.
Channel rules and state laws
Commercial email programs must respect CAN-SPAM requirements such as ad disclosure when applicable, a valid physical address, a clear opt-out, and prompt honor of opt-out requests (FTC CAN-SPAM guide). Telemarketing programs have their own disclosure, calling-hour, and do-not-call requirements under the Telemarketing Sales Rule (FTC TSR guide). State privacy, consent, and communications rules can add another layer, especially for SMS and outbound outreach, so operational review needs to happen before launch.
AI in medication adherence marketing
AI is making patient adherence programs smarter, but the real opportunity is not "automation." It is better timing, better prioritization, and better personalization.
The near-term use cases are already practical. A 2025 scoping review covering 52 studies found that adherence prediction models commonly rely on factors such as prior adherence, medication history, comorbidities, and socioeconomic variables, with random forest and logistic regression among the most frequent top-performing approaches (PubMed scoping review). That is exactly the kind of input set brand and support teams can use for predictive risk scoring.
AI is also already being used to improve execution. A review in Frontiers in Digital Health described AI applications ranging from mobile reminder systems and conversational refill support to computer-vision tools that confirm ingestion and chatbots that improve patient engagement (Frontiers review). The same review summarized examples including a conversational SMS refill program and chatbot support that improved compliance by more than 20% in one breast-cancer chatbot example (Frontiers review).
Natural language processing is expanding the toolkit further. A 2025 PubMed-indexed study used VADER and DistilRoBERTa models on 320,095 anonymized medication-experience reports to identify patient sentiments and emotions toward pharmacotherapy, and concluded that this kind of analysis can support more personalized and effective patient care strategies (PubMed sentiment study).
That said, the AI story is only good if governance is good. The Frontiers review also warns about privacy concerns, infrastructure demands, staff training needs, limited evidence bases, and the risk that engagement varies by race, ethnicity, language, age, and social determinants of health (Frontiers review). In other words, AI should help you triage patients more intelligently. It should not become an excuse to depersonalize care.
The brand-payer ROI story
Adherence is not just a patient-support metric. It is increasingly part of the payer conversation.
Value-based pharmaceutical contracts can use adherence and abandonment as measurable outcomes. UMass ForHealth notes that discounts in value-based contracts may be tied to factors such as clinical outcomes, patient adherence, abandonment rates, side effects, or dosage thresholds (UMass ForHealth). A value-based contracting guide from the Physicians Advocacy Institute similarly notes that medication adherence is used as a clinical and efficiency metric in these arrangements (Physicians Advocacy Institute guide).
The utilization story is just as compelling. An American Journal of Managed Care analysis found that missing medication-adherence quality measures was associated with increased healthcare resource utilization and higher costs, and concluded that adherence to these quality measures may reduce inpatient stays and emergency department visits by 21% to 50% and reduce total healthcare costs by 11% to 13% (AJMC).
That creates a more mature ROI argument for pharma brands: 1. Better adherence improves retained scripts. 2. Better adherence can improve patient outcomes. 3. Better adherence can lower avoidable utilization. 4. Better adherence can strengthen the brand’s value story with plans, providers, and employer stakeholders.
That is why the smartest adherence business cases no longer stop at refill lift. They connect adherence to persistence, persistence to outcomes, and outcomes to shared economic value.
Common mistakes
Most adherence programs fail for boring reasons, not exotic ones.
- Treating adherence like a reminders problem. Cost, side effects, confidence, and care-team friction do not disappear because a text went out.
- Starting too late. If support begins after the first missed refill, you are already behind.
- Building one journey for everyone. Low-risk and high-risk patients should not get the same sequence.
- Over-branding the experience. Patients in vulnerable moments need clarity and reassurance more than campaign polish.
- Separating marketing from support operations. If messaging, hub support, nurse outreach, analytics, and compliance are disconnected, patients feel the seams.
- Ignoring caregivers. In many chronic and rare conditions, adherence is a household behavior, not an individual one.
- Using weak measurement. Vanity engagement metrics are not enough; you need refill, persistence, and intervention impact.
- Forgetting the payer audience. If your program cannot tell a cost and outcomes story, you are leaving strategic value on the table.
FAQ
What are patient adherence programs?
Patient adherence programs are structured support programs designed to help people start, continue, and correctly use prescribed therapy over time. The need is substantial because the WHO reports that adherence to long-term therapy for chronic illness in developed countries averages 50%, and CDC/PubMed sources show that about one in five new prescriptions is never filled while many filled prescriptions are taken incorrectly (WHO adherence report; CDC Grand Rounds; PubMed).
What is the difference between adherence and persistence?
Adherence refers to how closely a patient follows the prescribed dosing schedule, while persistence refers to how long the patient stays on therapy before stopping (PubMed terminology paper). A later taxonomy paper defines persistence as the time between initiation and the last dose before discontinuation, and defines discontinuation as the point when the patient stops taking the medication (adherence taxonomy paper).
Should brands use MPR or PDC?
For most population-level reporting, PDC is the better anchor because CMS uses it in major medication-adherence measures and because PDC prevents overlap from pushing results above 100% (CMS Star Ratings Technical Notes; JMCP/PMC). MPR can still be useful, but overlap can inflate the result and methodology varies more widely (JMCP/PMC).
Are refill reminders considered marketing under HIPAA?
Not necessarily. HHS says refill reminders and certain medication-adherence communications about a drug currently being prescribed are excluded from HIPAA’s definition of marketing when the financial remuneration, if any, is reasonably related to the covered entity’s cost of making the communication (HHS refill reminder guidance). HHS also says the exception can apply to prescriptions that lapsed within the last 90 calendar days (HHS FAQ).
Can pharma brands use copay or financial support inside adherence programs?
Yes, but structure matters. OIG says low-risk cost-sharing waivers for Federal healthcare program enrollees generally need to be not routine, not advertised, and based on a good-faith individualized assessment of financial need (HHS OIG FAQs). That means affordability support should be built with legal review, clear eligibility logic, and careful messaging.
How is AI improving medication adherence marketing?
AI is helping teams predict nonadherence risk, personalize intervention timing, power conversational refill support, and analyze patient sentiment at scale (PubMed scoping review; Frontiers review; PubMed sentiment study). The best use of AI is not replacing human support; it is deciding who needs it, when, and why.
Build a smarter adherence engine with XDS Health
If your brand is serious about patient adherence programs, the work is bigger than reminders. You need journey design, behavior-informed content, compliant digital experiences, measurement architecture, and a program model that can hold both patient empathy and commercial accountability.
That is where XDS Health fits. XDS helps healthcare and life-sciences brands design patient and provider experiences that are strategically clear, operationally realistic, and built for measurable impact. For proof of that digital execution standard, take a look at the Cala Health case study.
If you are rethinking medication adherence marketing, start by aligning four layers at once: the patient journey, the support experience, the analytics model, and the compliance model. From there, you can build a program that actually changes behavior instead of just documenting drop-off.
For additional context, these XDS reads pair especially well with adherence planning: - Patient Journey Mapping for Life Sciences - HCP vs. Patient Marketing Strategy in Life Sciences - Healthcare Marketing Attribution and Measurement Guide - Important Safety Information Best Practices for Healthcare
Want help building an adherence experience that improves retention, respects compliance, and tells a better ROI story? XDS Health can help you design it.